TNFRSF17 and hematologic disorder: There are other CAR-Ts in clinical and preclinical research targeting BCMA and many other antigens [105,106], so we may expect encouraging results in the near future, however there is still no plateau in survival in contrast to that seen with CAR-T cells treatment in other hematologic malignancies.